ReviewCureus2026
Cardiovascular Outcomes and Vascular Surrogate Markers in Rheumatoid Arthritis Patients Treated With Anti-Tumour Necrosis Factor (TNF) Therapy: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is linked with a high risk of cardiovascular disease (CVD), which is mainly triggered by chronic systemic inflammation. Tumour necrosis factor (TNF) inhibitors are effective in managing RA disease activity; however, their impact on cardiovascular risk markers is also unclear. The systematic review and meta-analysis aimed to assess the effects of anti-TNF therapy on conventional cardiovascular risk markers, specifically lipid parameters and blood pressure, in patients with rheumatoid arthritis. We searched PubMed, Embase, Google Scholar, and the Cochrane Library for randomised controlled trials published after 2010 that compared anti-TNF therapy with control treatments in adults with RA; 4 trials met the inclusion criteria. The lipid parameters (low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein [HDL-C], triglycerides, and total cholesterol) and blood pressure were the outcomes. The Cochrane RoB 2.0 tool was used to measure risk of bias. Mean differences and 95% confidence intervals were used to produce random-effects meta-analyses. There were four randomised controlled trials with 295 participants. No statistically significant differences were found between the anti-TNF therapy and control groups for LDL-C, HDL-C, triglycerides, total cholesterol, systolic blood pressure, or diastolic blood pressure. The sensitivity analysis revealed that triglyceride results were unstable due to a single study, whereas the remaining results were very stable. In available RCTs, no statistically significant differences were observed between anti-TNF therapy and control treatments for conventional cardiovascular risk markers in patients with RA. More extensive and prolonged studies that include standardised cardiovascular outcomes should be undertaken to elucidate the cardiovascular effects of anti-TNF therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.